Beranda › Fibrosis Kistik › Alabama
Uji klinis Fibrosis Kistik di Alabama
16 studi untuk Fibrosis Kistik mencari peserta di lokasi di Alabama.
Kota di Alabama
Teks studi resmi (Bahasa Inggris)
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
- The Children's Hospital Alabama & University of Alabama at Birmingham, Birmingham
Menerima peserta
Usia 3 hingga 18 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT06654752Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children
- The Children's Hospital Alabama, University of Alabama at Birmingham, Birmingham
Menerima pesertaStudi observasional
Hingga usia 10 · Semua jenis kelamin · Diperbarui 8 Jul 2026 · NCT04509050Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
- The Children's Hospital Alabama, University of Alabama at Birmingham, Birmingham
Menerima pesertaFase 4
Usia 6 ke atas · Semua jenis kelamin · Diperbarui 8 Jul 2026 · NCT055482834D-710 in Adult Patients With Cystic Fibrosis
- University of Alabama Child Health Research Unit, Birmingham
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT05248230Ensuring Access to Optimal Therapy in CF: The ENACT Study
- The University of Alabama at Birmingham, Birmingham
Menerima pesertaFase 4
Usia 3 ke atas · Semua jenis kelamin · Diperbarui 2 Jun 2026 · NCT07148739Rare CFTR Mutation Cell Collection Protocol (RARE)
- University of Alabama at Birmingham, Birmingham
Menerima pesertaStudi observasionalMenyebutkan pembayaran untuk peserta
Usia 17 ke atas · Semua jenis kelamin · Diperbarui 29 Mei 2026 · NCT03161808Role of Body Fat Distribution in Metabolic and Pulmonary Decline in Cystic Fibrosis (ORBIT-CF)
- University of Alabama at Birmingham (UAB)/Children's of Alabama, Birmingham
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 16 ke atas · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT04002882Kidney Function in People With Cystic Fibrosis in the Era of HEMT
- University of Alabama at Birmingham, Birmingham
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 7 ke atas · Semua jenis kelamin · Diperbarui 4 Mei 2026 · NCT06595420Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
- University of Alabama at Birmingham, Birmingham
Menerima pesertaStudi observasional
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 10 Feb 2026 · NCT06837181Personalized Theratyping Trial
- University of Alabama at Birmingham, Birmingham
Menerima pesertaFase awal 1
Usia 6 ke atas · Semua jenis kelamin · Diperbarui 2 Feb 2026 · NCT03587961OnTrackCF: Engagement, Feasibility, and Acceptability Study
- University of Alabama-Birmingham, Birmingham
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Des 2025 · NCT07031323Health Outcomes of Parents With Cystic Fibrosis-Aim 2
- University of Alabama-Birmingham, Birmingham
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Nov 2025 · NCT06296394Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)
- University of Alabama at Birmingham, Birmingham
Menerima pesertaStudi observasional
Usia 6 ke atas · Semua jenis kelamin · Diperbarui 3 Nov 2025 · NCT06683092IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)
- University of Alabama at Birmingham, Birmingham
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2025 · NCT04294043A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
- The Children's Hospital Alabama, University of Alabama at Birmingham, Birmingham
Menerima pesertaStudi observasional
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2025 · NCT06504589Study With Phage for CF Subjects With Pseudomonas Lung Infection
- University of Alabama at Birmingham, Birmingham
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jul 2025 · NCT06998043Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.